5 results about "Macular edema" patented technology

The application discloses a kind of based on MEA-Net network's modeling method of multi-expert system, the application includes data pre-processing, cutting and proportionally distributing production image data and label data set;In order to improve fundus retinal lesion classification accuracy, the application designs Multi-Expert attention Net network model.Input module is preliminary extracted to data, replaceable expert network module is responsible for the depth analysis of feature, and voting module is strengthened by separating channel adjacent module on channel space to feature, and output weight realizes expert voting, finally, classification result is obtained by output module.The application can use the picture information of optical coherence tomography, can analyze and extract the characteristics of the four types of macular edema degeneration performances of OCT image PED, SRF, IRF, HRF, and lay the foundation for subsequent retinal disease classification and analysis to improve efficiency.

The invention provides a fundus macular oedema image processing method based on improved YOLOv11 and DeepSeek, and relates to the technical field of ophthalmic disease screening, and the method specifically comprises the steps: employing an improved YOLOv11 network structure, adding a lightweight dynamic convolution module LDConv module and a convolution block attention module CBAM, dynamically adjusting the shape and size of a convolution kernel, and carrying out the detection of the fundus macular oedema image. Multi-scale lesion characteristics such as macular edema and exudates are accurately captured; an attention map is generated through a channel and a space attention mechanism, key lesion areas of macular edema are preferentially concerned, interference of background noise is inhibited, and therefore accuracy and robustness of lesion recognition are further improved; a DeepSeek large language model is introduced, and on the basis of a detection result, personalized diagnosis and treatment suggestions conforming to clinical guidelines are generated in combination with clinical information (such as age, pathogenesis and treatment history) of patients; the system provides a structured treatment scheme and a follow-up visit plan and assists doctors in making more scientific and personalized decisions.

This invention relates to the application of an AAV carrying anti-VEGF recombinant protein in the prevention or treatment of proliferative diabetic retinopathy. After loading Fc-engineered VEGF antibody into an AAV vector, it can be used in drugs for the treatment of proliferative diabetic retinopathy. After injection, it can significantly improve the visual function of patients and reduce macular edema after a single dose. The anti-VEGF recombinant protein can be expressed for a long time, and can maintain the drug effect over a long period of time.

An ophthalmic formulation for treating macular edema, optic neuritis, and non-infectious endophthalmitis, comprising an active ingredient for treating an eye disease and a carrier or auxiliary material for the ophthalmic formulation, wherein the active ingredient for treating the eye disease is a glucocorticoid and / or nonsteroidal drug, and the carrier or auxiliary material for the ophthalmic formulation contains a surfactant, an ionic polymer, and a solvent, or the carrier or auxiliary material for the ophthalmic formulation contains low-degree-of-polymerization povidone, medium-degree-of-polymerization povidone, and a solvent. [Solution] This ophthalmic formulation, administered by eye drops, carries (encapsulates) glucocorticoid and / or nonsteroidal drugs, passes through the anterior segment of the eye, and is transported to the posterior segment to treat macular edema, optic neuritis, and non-infectious endophthalmitis. It has excellent clinical value and very positive social significance.